Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426107 | 1.00 | SMN1; SMN2 (0.64) | SMN1; SMN2RAB9AHPGDMEN1KMT2A | |
| SCHEMBL5423451 | 0.81 | EGFR (0.48) | RAB9AMEN1KMT2ANPC1KDM4E | |
| SCHEMBL5419496 | 0.80 | NPC1 (0.56) | SMN1; SMN2RAB9AHPGDMEN1KMT2A | |
| SCHEMBL15888632 | 0.78 | HPGD (0.67) | SMN1; SMN2RAB9AHPGDMEN1KMT2A | |
| SCHEMBL13162627 | 0.77 | MAPT (0.77) | SMN1; SMN2RAB9AHPGDMEN1KMT2A | |
| SCHEMBL13162950 | 0.77 | MAPT (0.77) | SMN1; SMN2RAB9AHPGDMEN1KMT2A | |
| SCHEMBL13162949 | 0.77 | MAPT (0.77) | SMN1; SMN2RAB9AHPGDMEN1KMT2A | |
| SCHEMBL5426101 | 0.76 | HPGD (0.55) | SMN1; SMN2RAB9AHPGDMEN1KMT2A | |
| SCHEMBL5421347 | 0.76 | HPGD (0.55) | SMN1; SMN2RAB9AHPGDMEN1KMT2A | |
| SCHEMBL13162030 | 0.76 | KMT2A (0.59) | SMN1; SMN2RAB9AHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-08 | — | — | US | claimed |
| EP-1551404-A2 | METHOD OF INHIBITING ANGIOGENESIS | Abbott Laboratories (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040116479-A1 | Method of inhibiting angiogenesis | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | claimed |
| WO-2004032908-A9 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LAB (US) | 2004-05-27 | — | — | WO | claimed |
| WO-2004032908-A2 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | claimed |
| US-20040067985-A1 | Method of inhibiting angiogenesis | ABBOT LABORATORIES | 2004-04-08 | — | — | US | claimed |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-22 | — | — | US | disclosed |
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-08 | — | — | US | disclosed |
| US-20040116479-A1 | Method of inhibiting angiogenesis | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| US-20040067985-A1 | Method of inhibiting angiogenesis | ABBOT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | PGF, VEGFA, FLT4 | SMN1; SMN2 4159/4885RAB9A 2668/4885HPGD 158/4885 |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | PGF, VEGFA, FLT4 | SMN1; SMN2 4159/4885RAB9A 2668/4885HPGD 158/4885 |
| US-20040067985-A1 | Method of inhibiting angiogenesis | VEGFA, PGF, FLT4 | SMN1; SMN2 4039/4885RAB9A 2825/4885HPGD 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.